Lilly to pay $400M to repurchase Cymbalta rights

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European partner Boehringer Ingelheim GmbH for an initial payment of $400 million.

Indianapolis-based Lilly, which owns the U.S. rights to the medicine, also will pay the closely held German drugmaker a royalty on Cymbalta sales through the end of 2012, the company said Monday in a statement. In Japan, Lilly shares marketing and development rights with Shionogi & Co.

Cymbalta sales gained 13 percent to $803.2 million in the first quarter, with 81 percent of the revenue coming from the United States, Lilly said Monday. Sales outside the U.S. rose 36 percent in the quarter.

The drug loses patent protection in 2013, and Lilly is seeking U.S. approval to sell it as a treatment for chronic pain.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
thisissue1-092914.jpg 092914

Subscribe to IBJ